|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated protective effects against diabetic kidney disease.
|
31701692 |
2020 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also summarize evidence for the effects of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium glucose co-transporter-2 inhibitors (SGLT-2i) versus placebo on the risk of major cardiovascular events (MACE), heart failure (HF) and diabetic kidney disease (DKD).
|
31495989 |
2020 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
A knowledge gap of DPP-4 inhibition in controlling renal fibrosis in DN has also been postulated in this review for future research perspectives.
|
31401210 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that DPP-4 inhibition can be relevant for combating proteinuric DKD by targeting the EMT program induced by the crosstalk among DPP-4, integrin β1 and CAV1.
|
31101909 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Switching to teneligliptin from other DPP-4 inhibitors for 24 weeks reduces plasma DPP-4 activity, which is associated with a reduction in albuminuria, independent of the change in glucose levels, in type 2 diabetes mellitus patients with diabetic kidney disease.
|
30136384 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sitagliptin, an inhibitor of DPP-IV plays a beneficial role in type 2 diabetic nephropathy.
|
30940309 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to detect early signs of DN and study the potential ameliorating effect of the dipeptidyl peptidase-4 inhibitor, linagliptin, on some early markers for DN in fructose-streptozotocin (Fr-STZ)-induced diabetic rats.
|
30699409 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The hypoglycemic drugs dipeptidyl peptidase-4 (DPP-4) inhibitors have proven protective effects on diabetic kidney disease, including renal fibrosis.
|
30877711 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
DPP-4 inhibitors can be used safely in patients with diabetic kidney disease and do not appear to exacerbate existing diabetic nephropathy.
|
30848158 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the globally marketed DPP-4 inhibitors, linagliptin is of particular interest for diabetic nephropathy as it is the only compound that is not predominantly excreted in the urine.
|
29491123 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
To focus on the potential beneficial effects of the pleiotropic effects of dipeptidyl peptidase-4 inhibitors (DPP4is) on attenuating progression of diabetic kidney disease in reducing the long-term effect of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition.
|
30343892 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy.
|
30425192 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dipeptidyl peptidase-4 (DPP4) inhibitors are known to have a protective effect on diabetic kidney disease, possibly via reduction of oxidative stress and inflammation in the kidney.
|
29913457 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of dapagliflozin (Dapa) on the activation of the Nlrp3 inflammasome and the combined effect of SGLT2 and DPP4 on T2DM-induced inflammasome activation and progression of DN have not been previously studied.
|
29508169 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The DPP-4 inhibitor, linagliptin, was evaluated with the hypothesis that DPP-4 inhibition would ameliorate the development of DKD in a glucose-independent manner by altering specific antioxidant function.
|
29979777 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
More importantly, results from the reviewed studies indicate that DPP-4 inhibitor therapy may improve two major risk factors for diabetic nephropathy, such as hyperglycemia and albuminuria, resulting in potential renal benefits beyond glycemic control.
|
29223646 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical animal studies and some clinical data suggest that DPP-4 inhibitors decrease the progression of diabetic nephropathy in a blood pressure- and glucose-independent manner.
|
28420715 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase 4 inhibitor (DPP4i) use potentially slows the progression of diabetic kidney disease, but its effects on the risk of acute kidney injury (AKI) are unclear.
|
28881791 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significant increases occurred in the uptake of new diabetic medications; DPP-4 inhibitors and SGLT-2 inhibitors and in the utilization of ACEIs and ARBs compared to the findings reported in other studies with increased complexity in the treatment of patients with diabetic nephropathy.
|
28295491 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
|
28329747 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This arises the question whether the use of DPP-4 inhibitors might serve as an additional therapeutic strategy to prevent proteinuria in patients with DKD.
|
27625045 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of stromal cell-derived factor-1 (SDF-1) in the pathogenesis of diabetic nephropathy and its modification by dipeptidyl peptidase-4 (DPP-4) inhibition are uncertain.
|
27475229 |
2016 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of DPP-4 by linagliptin might be a promising strategy for the treatment of diabetic nephropathy.
|
24710699 |
2014 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we discuss the GLP-1 (glucagon-like peptide-1) receptor agonists and DPP-4 (dipeptidyl peptidase-4) inhibitors (incretin-based therapies), which are novel antidiabetic agents used in clinical practice and their role in diabetic nephropathy with specific focus on renoprotection and surrogate markers of cardiovascular disease.
|
22963445 |
2013 |